SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-029935
Filing Date
2019-02-07
Accepted
2019-02-06 21:40:01
Documents
5
Period of Report
2019-02-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d684752d8k.htm 8-K 26708
2 EX-1.1 d684752dex11.htm EX-1.1 293527
3 EX-4.1 d684752dex41.htm EX-4.1 62120
4 EX-5.1 d684752dex51.htm EX-5.1 16211
5 GRAPHIC g684752g0206114553117.jpg GRAPHIC 7532
  Complete submission text file 0001193125-19-029935.txt   410352
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 19573290
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1